ARTICLE | Company News

Biogen Idec biopharmaceuticals news

June 23, 2008 7:00 AM UTC

Biogen Idec said shareholders voted in favor of the company’s slate of four board members, thus defeating an opposing trio of directors put forth by Carl Icahn. The results are expected to be finalized within two to three weeks and would result in the reelection of current directors Cecil Pickett, Lynn Schenk and Philip Sharp and the appointment of Stelios Papadopoulos, retired Vice Chairman of Cowen and Company LLC. Papadopoulos would replace Thomas Keller, who is retiring. Shareholders also rejected Icahn’s proposal to set the number of directors at 12. The financier had hoped to restructure the board and restart efforts to sell the company (see BioCentury, Feb. 4). ...